Prime Medicine, Inc. (PRME) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 146.20M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 26.77M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -196.52M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $146.20M | (m) | $26.77M | $-196.52M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $154.18M | (m) | $28.23M | $-206.61M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $160.64M | $4.63M | $29.27M | $-208.35M | (m) | 3467.96% | 631.87% | (m) | (m) |
| 2025-09-30 | $160.03M | $5.98M | $30.69M | $-203.96M | (m) | 2677.45% | 513.54% | (m) | (m) |
| 2025-06-30 | $156.38M | $4.96M | $24.77M | $-204.22M | (m) | 3152.21% | 499.38% | (m) | (m) |
| 2025-03-31 | $158.08M | $3.85M | $26.54M | $-206.52M | (m) | 4110.17% | 690.07% | (m) | (m) |
| 2024-12-31 | $155.29M | $2.98M | $26.07M | $-202.47M | (m) | 5205.80% | 873.89% | (m) | (m) |
| 2024-09-30 | $162.64M | (m) | $24.56M | $-226.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $163.27M | (m) | $21.95M | $-223.51M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $154.80M | (m) | $17.44M | $-213.10M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $147.91M | (m) | $13.91M | $-204.79M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $12.05M | $-175.44M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $9.26M | $-155.63M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $103.93M | (m) | $7.02M | $-136.68M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $86.72M | $0.00 | $6.46M | $-116.54M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $70.55M | $0.00 | $1.75M | $-84.47M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $2.98M | $5.21M | $391.00K | $-932.00K | (m) | 57.20% | 7.50% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |